Dopamine Agonist News and Research

RSS

Deep brain stimulation may improve quality of life in Parkinsons disease

Researchers compare the impact of medication alone or deep brain stimulation of the subthalamic nuclei in quality of life in Parkinson's patients.

22 Jan 2024

Research reveals the role of dopamine in how songbirds learn complex new sounds

Neuroscientists at the University of Massachusetts Amherst have demonstrated in new research that dopamine plays a key role in how songbirds learn complex new sounds.

5 Jul 2021

Impulse control disorders found to be more common in people taking Parkinson's drugs

Over time, half of the people taking certain drugs for Parkinson's disease may develop impulse control disorders such as compulsive gambling, shopping or eating, according to a study published in the June 20, 2018, online issue of Neurology®, the medical journal of the American Academy of Neurology.

20 Jun 2018

New drug may limit disease progression, provide better symptom relief to Parkinson's patients

Researchers at Binghamton University have developed a new drug that may limit the progression of Parkinson's disease while providing better symptom relief to potentially hundreds of thousands of people with the disease.

31 Jul 2017

Increased sleepiness may necessitate cautious PD management

Many patients with early Parkinson’s disease develop excessive daytime sleepiness as their condition progresses, a study shows.

3 Jul 2015

Clinical studies confirm safety, efficacy of opicapone in Parkinson’s disease patients

BIAL is presenting 11 research posters at the 19th International Congress of Parkinson's Disease and Movement Disorders (June 14–15, San Diego, CA). These evaluate the safety and efficacy of opicapone (BIA 9-1067), a novel once-daily catechol-O-methyltransferase (COMT) inhibitor for use as adjunctive therapy in levodopa-treated Parkinson’s disease patients with end of dose motor fluctuations.

15 Jun 2015

Impulse control disorders do not promote cognitive decline in PD

Impulse control disorders in patients with Parkinson’s disease are not associated with more marked impairment of cognitive function, researchers report.

7 Apr 2015

Creatine monohydrate disappoints in Parkinson’s disease

Creatine monohydrate fails to live up to its early promise in patients with Parkinson’s disease, show the results of the Long-term Study 1.

13 Mar 2015

Perceived cost affects placebo response in Parkinson’s disease

Patients with Parkinson’s disease may gain a greater benefit from a placebo treatment if they believe it to be expensive, research suggests.

27 Feb 2015

Creatine monohydrate disappoints in Parkinson’s disease

Creatine monohydrate fails to live up to its early promise in patients with Parkinson’s disease, show the results of the Long-term Study 1.

13 Feb 2015

Childhood macroprolactinomas amenable to dopamine agonist treatment

Dopamine agonist treatment normalises prolactin levels in about three-quarters of children with macroprolactinomas, show findings from a large series.

30 Jan 2015

Newron, Zambon announce re-submission of safinamide NDA to FDA

Newron Pharmaceuticals S.p.A., a research and development company focused on novel CNS and pain therapies, and its commercial and development partner Zambon S.p.A., an international pharmaceutical company, announced today that the NDA for safinamide has been re-submitted to the US FDA.

29 Dec 2014

Non-ergot derived dopamine agonists may be safe for the heart

Non-ergot derived dopamine agonists used to treat Parkinson's disease may be safe for the heart, according to preliminary research presented at EuroEcho-Imaging 2014 by Dr Hilal Erken Pamukcu, cardiologist at Ankara Diskapi Education and Research Hospital in Turkey.

4 Dec 2014

Naltrexone may be effective in diminishing ICD symptoms in PD patients, study finds

Up to 20 percent of Parkinson's disease (PD) patients and their families may confront a common but largely unrecognized challenge: the occurrence of impulse control disorders (ICDs) such as compulsive gambling, sexual behavior, eating, or spending.

31 Jul 2014

Newron Pharmaceuticals submits safinamide NDA to FDA

Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area with a long experience in respiratory disease therapies, woman care and primary care, announce that the New Drug Application (NDA) for safinamide was submitted today to the US Food and Drug Administration (FDA).

30 May 2014

Study: Depression in Parkinson's patients may reflect impaired striatal dopamine function

According to the Parkinson's Disease Foundation, up to 60% of individuals with Parkinson's disease (PD) exhibit mild to moderate depression, which is often underdiagnosed.

11 Oct 2013

Depression in Parkinson's disease people associated with reduced dopamine synthesis capacity

According to the Parkinson's Disease Foundation, up to 60% of individuals with Parkinson's disease exhibit mild to moderate depression, which is often underdiagnosed. It is unclear whether depression results from having a debilitating disease or reflects a parallel abnormal change in the brain caused by PD pathophysiology.

11 Oct 2013

Drugs often fail to bring acromegaly under control in routine clinical practice

Over a quarter of UK patients treated for growth hormone-producing tumours do not achieve 'safe' growth hormone levels, according to a 30 year UK multi-centre study of clinical management of the rare disease acromegaly. The findings by the Society for Endocrinology UK Acromegaly Register, published in the November issue of Clinical Endocrinology, show that drugs to control acromegaly often fail to bring the disease completely under control in routine clinical practice.

10 Oct 2013

Neuroscientists honored for research into brain's reward and decision-making systems

Maximum reward, minimum punishment: these are the maxims humans and animals often apply when making decisions. A network of nerve cells in the brain conveys gratification.

12 Sep 2013

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.

19 Jun 2013

Dopamine Agonist News and Research

Deep brain stimulation may improve quality of life in Parkinsons disease

Research reveals the role of dopamine in how songbirds learn complex new sounds

Impulse control disorders found to be more common in people taking Parkinson's drugs

New drug may limit disease progression, provide better symptom relief to Parkinson's patients

Increased sleepiness may necessitate cautious PD management

Clinical studies confirm safety, efficacy of opicapone in Parkinson’s disease patients

Impulse control disorders do not promote cognitive decline in PD

Creatine monohydrate disappoints in Parkinson’s disease

Perceived cost affects placebo response in Parkinson’s disease

Creatine monohydrate disappoints in Parkinson’s disease

Childhood macroprolactinomas amenable to dopamine agonist treatment

Newron, Zambon announce re-submission of safinamide NDA to FDA

Non-ergot derived dopamine agonists may be safe for the heart

Naltrexone may be effective in diminishing ICD symptoms in PD patients, study finds

Newron Pharmaceuticals submits safinamide NDA to FDA

Study: Depression in Parkinson's patients may reflect impaired striatal dopamine function

Depression in Parkinson's disease people associated with reduced dopamine synthesis capacity

Drugs often fail to bring acromegaly under control in routine clinical practice

Neuroscientists honored for research into brain's reward and decision-making systems

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News